Medtronic Inc. (NYSE:MDT) shares fell 1.4% on Friday . The stock traded as low as $86.25 and last traded at $86.69, with a volume of 4,420,010 shares changing hands. The stock had previously closed at $87.94.

Several research firms have recently weighed in on MDT. Bank of America Corp. reissued a “buy” rating on shares of Medtronic in a report on Sunday, May 22nd. Vetr raised shares of Medtronic from a “buy” rating to a “strong-buy” rating and set a $89.50 price objective for the company in a report on Monday, May 2nd. BTIG Research lowered shares of Medtronic from a “buy” rating to a “neutral” rating and set a $82.00 target price for the company. in a research report on Tuesday, May 31st. Zacks Investment Research lowered shares of Medtronic from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Monday, June 27th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $87.88.

The firm’s 50 day moving average is $86.07 and its 200 day moving average is $79.25. The stock has a market cap of $121.48 billion and a price-to-earnings ratio of 35.12.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, May 31st. The medical technology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.01. The firm had revenue of $7.57 billion for the quarter, compared to analysts’ expectations of $7.49 billion. During the same period last year, the firm earned $1.16 earnings per share. Medtronic’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts expect that Medtronic Inc. will post $4.66 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 27th. Stockholders of record on Friday, July 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 1.97%. This is a positive change from Medtronic’s previous quarterly dividend of $0.38. The ex-dividend date is Wednesday, July 6th.

In other news, Director Shirley A. Jackson sold 2,104 shares of Medtronic stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $88.64, for a total transaction of $186,498.56. Following the completion of the transaction, the director now directly owns 34,503 shares of the company’s stock, valued at approximately $3,058,345.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Geoffrey Martha sold 3,766 shares of Medtronic stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $88.26, for a total transaction of $332,387.16. The disclosure for this sale can be found here.

Other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Medtronic by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 89,739,674 shares of the medical technology company’s stock valued at $6,902,776,000 after buying an additional 2,935,600 shares during the period. Wells Fargo & Company MN raised its position in Medtronic by 2.0% in the fourth quarter. Wells Fargo & Company MN now owns 13,110,194 shares of the medical technology company’s stock valued at $1,008,436,000 after buying an additional 253,096 shares during the period. Morgan Stanley raised its position in Medtronic by 12.1% in the fourth quarter. Morgan Stanley now owns 9,095,598 shares of the medical technology company’s stock valued at $699,632,000 after buying an additional 979,589 shares during the period. Dimensional Fund Advisors LP raised its position in Medtronic by 63.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,347,687 shares of the medical technology company’s stock valued at $334,447,000 after buying an additional 1,680,556 shares during the period. Finally, OppenheimerFunds Inc. raised its position in Medtronic by 2.9% in the fourth quarter. OppenheimerFunds Inc. now owns 2,299,012 shares of the medical technology company’s stock valued at $176,848,000 after buying an additional 64,493 shares during the period.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.